{"filing":{"accession_number":"0001104659-26-085790","cik":"0001626971","ticker":"CRVS","company_name":"Corvus Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"crvs-20260721x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1626971/000110465926085790/crvs-20260721x8k.htm"},"events":[{"id":19459,"run_id":17517,"accession_number":"0001104659-26-085790","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Ian T. Clark resigned from the Board of Directors of Corvus Pharmaceuticals, effective July 22, 2026, after over nine years of service. The disclosure centers on a director's departure, making this a clear exec_departure event. Board changes are material to investors assessing governance and leadership continuity.","company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18553,"accession_number":"0001104659-26-085790","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Ian T. Clark resigned from the Board of Directors of Corvus Pharmaceuticals, effective July 22, 2026, after over nine years of service. The disclosure centers on a director's departure, making this a clear exec_departure event. Board changes are material to investors assessing governance and leadership continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:04:48.750794+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18553,"accession_number":"0001104659-26-085790","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Ian T. Clark resigned from the Board of Directors of Corvus Pharmaceuticals, effective July 22, 2026, after over nine years of service. The disclosure centers on a director's departure, making this a clear exec_departure event. Board changes are material to investors assessing governance and leadership continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:04:48.750794+00:00","company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","filing_date":"2026-07-22"}]}